A technology that could bring better, safer treatments to cancer patients worldwide might have fallen through the cracks. Now Tomotherapy, a Madison medical-device firm with more than 200 employees that has grown to $44 million in sales, could go public within a year, its founder said.
The company is run by Thomas “Rock” Mackie, a UW-Madison professor who was spurred into going commercial when GE Medical cut off its funding for his radiology projects.